Filtered By:
Specialty: Cancer & Oncology
Cancer: Glioma

This page shows you your search results in order of date.

Order by Relevance | Date

Total 27 results found since Jan 2013.

Eloquent Lower Grade Gliomas, a Highly Vulnerable Cohort: Assessment of Patients ’ Functional Outcome After Surgery Based on the LoG-Glio Registry
Majority of lower grade glioma (LGG) are located eloquently rendering surgical resection challenging. Aim of our study was to assess rate of permanent deficits and its predisposing risk factors. We retrieved 83 patients harboring an eloquently located LGGs from the prospective LoG-Glio Database. Patients without surgery or incomplete postoperative data were excluded. Sign rank test, explorative correlations by Spearman ρ and multivariable regression for new postoperative deficits were calculated. Eloquent region involved predominantly motor (45%) and language (40%). At first follow up after 3 months permanent neuro-logica...
Source: Frontiers in Oncology - March 3, 2022 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 14, Pages 1207: Intercellular Communication in the Brain through Tunneling Nanotubes
Vignais Intercellular communication is essential for tissue homeostasis and function. Understanding how cells interact with each other is paramount, as crosstalk between cells is often dysregulated in diseases and can contribute to their progression. Cells communicate with each other through several modalities, including paracrine secretion and specialized structures ensuring physical contact between them. Among these intercellular specialized structures, tunneling nanotubes (TNTs) are now recognized as a means of cell-to-cell communication through the exchange of cellular cargo, controlled by a variety of biological t...
Source: Cancers - February 25, 2022 Category: Cancer & Oncology Authors: Khattar E. Khattar Janice Safi Anne-Marie Rodriguez Marie-Luce Vignais Tags: Review Source Type: research

Combination treatment for common glioma type shows promise in mice
(NIH/National Institute of Neurological Disorders and Stroke) Gliomas are common brain tumors that comprise about one third of all cancers of the nervous system. In a study funded by the National Institutes of Health (NIH), researchers tested a novel combination treatment approach on mice with tumors with characteristics similar to human astrocytomas and found tumor regression in 60 percent of the mice treated. These encouraging results could be the first step toward developing a treatment for this type of brain cancer.
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news

Drugs against alpha-ketoglutarate may combat deadly childhood brain tumor
(NIH/National Institute of Neurological Disorders and Stroke) Every year, 150 to 300 children in the United States are diagnosed with diffuse intrinsic pontine gliomas (DIPGs), aggressive and lethal tumors that grow deep inside the brain, for which there are no cures. In a study funded by the National Institutes of Health, researchers showed that experimental drugs designed to lower the body's natural production of alpha-ketoglutarate extended the lives of mice harboring DIPG tumors by slowing the growth of the cancer cells.
Source: EurekAlert! - Cancer - August 18, 2020 Category: Cancer & Oncology Source Type: news

NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
Conclusion and Perspectives Gliomas are the most prevalent primary brain cancer in adults and include a broad category of tumors including astrocytoma, oligodendroglioma, and GBM. Regardless of tumor aggressiveness, malignancy, and infiltration, these glia-derived tumors rarely exceed a median survival time of 12–14 months. Driven by the infiltrative nature of these tumors, the clinical approach is difficult and relapses often occur with fatal consequences. These unsuccessful attempts to control glioma's fate have fostered research looking for more effective therapies. (GSCs) are a small subset of CD133&#...
Source: Frontiers in Oncology - May 2, 2019 Category: Cancer & Oncology Source Type: research

Study unveils a blueprint for treating a deadly brain tumor
(NIH/National Institute of Neurological Disorders and Stroke) In a study of mice and human brain tumors researchers at the University of the Michigan, Ann Arbor, searched for new treatments by exploring the reasons why some patients with gliomas live remarkably longer than others. The results suggested that certain patients' tumor cells are less aggressive and much better at repairing DNA than others but are difficult to kill with radiation. The researchers then showed that combining radiation therapy with cancer drugs designed to block DNA repair may be an effective treatment strategy.
Source: EurekAlert! - Cancer - February 19, 2019 Category: Cancer & Oncology Source Type: news

Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients
ConclusionWe hypothesize that the late onset phenomenon of NCES predominantly represents a form of radiation-induced vasculopathy that is different from early pseudoprogression and should be considered especially in younger patients with IDH-mutated glioma before initiation of new therapy.
Source: Journal of Neuro-Oncology - January 2, 2019 Category: Cancer & Oncology Source Type: research

Features of diffuse gliomas that are misdiagnosed on initial neuroimaging: a case control study
ConclusionSeveral clinical and radiologic metrics are associated with diffuse gliomas that are missed or misdiagnosed on the initial neuroimaging study. Knowledge of these associations may aid in avoiding misinterpretation and accurately diagnosing such cases in clinical practice.
Source: Journal of Neuro-Oncology - October 1, 2018 Category: Cancer & Oncology Source Type: research

Researchers hit the brakes on lethal brain cancers in mice
(NIH/National Institute of Neurological Disorders and Stroke) New research conducted in mice provides evidence that highly lethal brain tumors, called high-grade gliomas, stop growing when deprived of a specific molecule naturally produced when brain cells fire. The experiments, led by a group of scientists from Stanford University, Palo Alto, California, suggest that targeting a protein called neuroligin-3 may prove beneficial in patients with these diseases.
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Therapeutic dormancy to delay postsurgical glioma recurrence: the past, present and promise of focal hypothermia
AbstractSurgery precedes both radiotherapy and chemotherapy as the first-line therapy for glioma. However, despite multimodal treatment, most glioma patients die from local recurrence in the resection margin. Glioma surgery is inherently lesional, and the response of brain tissue to surgery includes hemostasis, angiogenesis, reactive gliosis and inflammation. Unfortunately, these processes are also associated with tumorigenic side-effects. An increasing amount of evidence indicates that the response to a surgery-related brain injury is hijacked by residual glioma cells and participates in the local regeneration of tumor ti...
Source: Journal of Neuro-Oncology - May 17, 2017 Category: Cancer & Oncology Source Type: research

Vascular complications in glioma patients.
Abstract Vascular complications in patients with glioma most commonly include venous and arterial thromboembolism; however, treatment-induced vasculopathies are also problematic, especially in long-term survivors. The interactions between treatment such as radiation and chemotherapy, the coagulation cascade, endothelium, and regulators of angiogenesis are complex, drive glioma growth and invasion, and create common management problems in the clinic. We review the incidence of thrombotic complications in glioma, the biology of the coagulome as related to glioma progression, prevention and treatment of thrombosis, t...
Source: Clinical Genitourinary Cancer - December 16, 2016 Category: Cancer & Oncology Authors: Le Rhun E, Perry JR Tags: Handb Clin Neurol Source Type: research

Atim-02. successful cancer-selective gene delivery following intravenous toca 511 delivery in patients with recurrent high grade glioma (hgg)
This study demonstrates successful gene transduction following IV delivery of Toca 511 and shows encouraging survival data. Updated safety and efficacy data will be presented.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Cloughesy, T., Walbert, T., Bota, D., Vogelbaum, M., Liau, L., Ostertag, D., Jolly, D., Gruber, H., Yang, L., Shorr, J., Kalkanis, S. Tags: ADULT CLINICAL TRIALS (IMMUNOLOGICAL) Source Type: research

Ntox-08. safety of intra-arterial chemotherapy in the treatment of brain tumours
The treatment of brain tumors is greatly limited the delivery impediment caused by the blood-brain barrier and blood-tumor barrier. To circumvent this limitation, different approaches have been studied, including intra-arterial delivery. Because of a significant local increase in plasma-peak concentration, this strategy increases the local area under the curve, and translates into a 3 to 5.5 fold increase in intra-tumoral chemotherapy concentration. However, intra-arterial chemotherapy in the treatment of brain tumors has a notoriously bad name, thanks to prior trials led in past decades showing significant neurotoxicities...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Fortin, D., Caux, S., Gahide, G. Tags: NEUROTOXICITY OF THERAPY Source Type: research

Atim-18. phase i dose escalation study of d2c7-it administered intratumorally via convection-enhanced delivery (ced) for recurrent malignant glioma (mg)
CONCLUSION:Infusion of D2C7-IT via CED is safe thus far and encouraging efficacy results are observed. Enrollment is ongoing.
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Desjardins, A., Randazzo, D., Chandramohan, V., Sampson, J., Peters, K., Vlahovic, G., Threatt, S., Herndon, J., Boulton, S., Lally-Goss, D., Healy, P., Lipp, E., Friedman, A., Friedman, H., Bigner, D. Tags: ADULT CLINICAL TRIALS (IMMUNOLOGICAL) Source Type: research